AUTHORS
Joseph Tripodi, PhD, Colin Butler2, Brandon Vermis, DDS3, Daiva Ahire, MS4, John O. Mascarenhas, MD5, Ronald Hoffman, MD6, Vesna Najfeld, PhD7
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Background: Copy-neutral loss of heterozygosity (CNLOH) is a recurrent abnormality in myeloproliferative neoplasms (MPNs). Unlike CNLOH 9p, which results in homozygosity for the JAK2 V617F mutation, CNLOH 14q is a rare but recurrent abnormality that does not appear to target a recurrently mutated gene, and its clinical consequences remain poorly understood. In a study of patients (pts) with myeloid malignancies and elderly individuals without hematologic malignancy, CNLOH of 14q resulted in loss of the maternal and duplication of the paternal allele, implicating the imprinted delta-like non-canonical notch ligand 1 (DLK1) and maternally expressed 3 (MEG3) locus at 14q32 (Chase et al., Leukemia, 2015). This locus encodes the paternally expressed DLK1, a non-canonical notch ligand, and maternally expressed noncoding RNAs including the lncRNA MEG3, a putative tumor suppressor that promotes p53 activity. The imprinted DLK1-MEG3 locus plays a critical role in the maintenance and differentiation of hematopoietic stem cells (Sellers et al., Clinical Epigenetics 2019). This region also contains the T-cell leukemia/lymphoma 1A gene (TCL1A) which encodes a proto-oncogene that functions primarily as a co-activator of the AKT signaling pathway (Laine et al., Mol Cell, 2000). In vitro models showed that forced expression of TCL1A promoted the expansion of human HSCs (Weinstock et al., Nature, 2023). Recently, a cohort of 451,180 individuals with available exome data, excluding those with a hematological malignancy, demonstrated increased co-occurrence of JAK2 V617F and CNLOH 14q, raising the possibility that TCL1A activation contributes to the stem cell fitness advantage conferred by specific driver mutations in pts with clonal hematopoiesis (Kishtagari et al., Blood Cancer J, 2024). The aim of this study was to determine the prevalence, genomic correlates, and significance of CNLOH 14q in MPNs.
Methods: We retrospectively studied 670 pts with MPNs, including essential thrombocythemia (ET; n=176), polycythemia vera (PV; n=122), pre-fibrotic primary myelofibrosis (pre-PMF; n=36), primary myelofibrosis (PMF; n=225), MPN not otherwise specified (MPN-NOS; n=70), and MPN in accelerated or blast phase (MPN-AP/BP; n=41), who had chromosomal microarray analysis (CMA) between November 2017 and June 2026. Clinical, morphologic, cytogenetic, and molecular data, including driver mutation status and next-generation sequencing panel results were reviewed.
Results: Among the 670 pts evaluated by CMA, CNLOH 14q was identified in 15 (2%) pts. The CNLOH 14q cohort included 13 pts with PMF, one with PV, and one with MPN-NOS. Nine pts were male and six were female, with a median age at testing of 74.6 years (range, 26–83 years). Two patterns of CNLOH 14q were identified: interstitial and terminal. Three pts had interstitial CNLOH 14q, whereas the remaining 12 involved terminal regions of variable size, all extending to the telomeres of the long arms of chromosome 14 (14qter). The minimal overlapping region was an 11.6-Mb segment spanning 14q32.13–q32.33 and containing more than 200 genes, including the imprinted DLK1-MEG3 locus and TCL1A gene. Six of the 15 pts (40%) had a normal karyotype, with CMA revealing cryptic chromosomal abnormalities. Concurrent CNLOH 9p encompassing JAK2 was present in 5 pts. Additional recurrent abnormalities included del(13q) (n=4), CNLOH 1p (n=3), and complex karyotype (n=2). Molecular profiling identified JAK2 V617F in seven pts, with variant allele frequencies ranging from 37% to 88%; CALR mutations in 5; MPL mutations in 2; and a triple-negative genotype in one. High-molecular-risk mutations were identified in five pts. Recurrently mutated genes included ASXL1 (n=4), TET2 (n=4), SRSF2 (n=2), and U2AF1 (n=1). Overall, seven pts (47%), all having PMF, exhibited adverse genomic features including high-molecular-risk mutations (n=4), complex karyotype (n=2), or both (n=1).
Conclusions: Our results identified CNLOH 14q by CMA in 2% of pts with MPN, which occurred predominantly in pts with PMF (13/225, 6%). These pts had complex karyotypes or high-risk molecular features, suggesting that CNLOH 14q may characterize a clinically distinct genetic subset of MPN pts. The minimal overlapping region encompassed the imprinted DLK1-MEG3 locus and TCL1A gene, supporting a potential role for allele-specific gene dysregulation in a clonal expansion mechanism distinct from acquired mutation homozygosity.
DISCLOSURES
Joseph Tripodi, PhD: No relevant conflicts of interest to declare.